Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 2,819 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: matched control group Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 41
States / cities: Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Interventions: LIK066, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Baton Rouge, Louisiana • St Louis, Missouri • Knoxville, Tennessee + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Metformin XR, Metformin IR, Placebo matching with Metformin XR, Placebo matching with Metformin IR; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 39
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 29 more

Conditions: Hepatic Impairment
Interventions: Camizestrant; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Bullying
Interventions: BullyDown, Attention-matched control; Behavioral
Lead sponsor: Center for Innovative Public Health Research; Other
Eligibility: 12 Years to 14 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: San Clemente, California • Chapel Hill, North Carolina

Conditions: Crohn's Disease
Interventions: Ontamalimab, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 73
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 62 more

Conditions: Stress, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Mindfulness Based Stress Reduction, Stress Management Education; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Obesity
Interventions: JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3, Liraglutide, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 17
States / cities: Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 34
States / cities: Birmingham, Alabama • Anchorage, Alaska • Oakland, California + 30 more

Conditions: Obesity, Overweight and Obesity, Overweight
Interventions: Tirzepatide; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Eosinophilic Esophagitis
Interventions: Famotidine, Loratadine, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Hemophilic Arthropathy
Interventions: TRM-201 (Rofecoxib), Placebo; Drug
Lead sponsor: Tremeau Pharmceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 19
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 15 more

Conditions: Pain
Interventions: Cognitive bias modification, Standard attentional bias; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Parkinson Disease
Interventions: Tavapadon, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 54
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more

Conditions: Autism Spectrum Disorder
Interventions: Cognitive Support Technology (CST); Behavioral
Lead sponsor: Kent State University; Other
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Kent, Ohio

Conditions: Severe Alopecia Areata
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 9
States / cities: Los Angeles, California • Miami, Florida • Meridian, Idaho + 6 more

Conditions: Opioid Use, Postpartum Disorder, Chronic Pain Syndrome
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Tobacco Dependence
Interventions: Nicotine Spray, Placebo; Drug
Lead sponsor: McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Scottsdale, Arizona • Burbank, California • Chicago, Illinois + 5 more

Conditions: Insomnia Disorder
Interventions: ACT-541468 5 mg, ACT-541468 10 mg, ACT-541468 25 mg, Zolpidem, Placebo 1, Placebo 2; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 15
States / cities: Santa Monica, California • Upland, California • Brandon, Florida + 12 more

Conditions: Long COVID, Long COVID-19, Hypersomnia
Interventions: Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Post-Traumatic Stress Disorder
Interventions: PF-04457845, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: New York, New York

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab, Placebo; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 18 more

Conditions: Infantile Spasm
Interventions: Cannabidiol Oral Solution, Placebo, Vigabatrin; Drug
Lead sponsor: Radius Pharmaceuticals, Inc.; Industry
Eligibility: 1 Month to 24 Months
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Miami, Florida • Royal Oak, Michigan • Akron, Ohio + 2 more

Conditions: Major Depressive Disorder
Interventions: Creatine monohydrate, Placebo; Dietary Supplement · Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

BullyDown, a Text Messaging-based Bullying Prevention Program for Middle School-aged Youth

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

Decreasing Stress in Diabetes

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation

Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

Antihistamines in Eosinophilic Esophagitis

Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

Opioid and Pain Cognition

Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)

Cognitive Support Technology for Postsecondary Students With Autism Spectrum Disorder

A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata

Prevention of Persistent Opioid Use in Mothers

Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)

A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms

A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder